H.B. Fuller Company (FUL) reports Q2 2026 results: 5.8% revenue growth, $181M EBITDA, and strategic acquisition of AMS announced.

Key Takeaways

• Revenue in Q2 2026 rose 5.8% year-over-year, driven by pricing initiatives and operational efficiencies.
• Adjusted EBITDA reached $181 million, marking a 9% increase compared to the same quarter last year.
• Adjusted EPS stood at $1.41, reflecting a 19% growth year-on-year.
• The company announced an all-cash offer for Advanced Medical Solutions (AMS) at £285 per share, implying a total enterprise value of approximately £715 million.
• Organic revenue growth was 2.6%, primarily due to 3% pricing, despite slight volume declines.

Financial Performance

In the second quarter of 2026, H.B. Fuller Company demonstrated robust financial performance, with a year-over-year revenue increase of 5.8%. This growth was attributed to effective pricing strategies that contributed 3% to organic growth, countered slightly by a minor dip in sales volume. The adjusted EBITDA reached $181 million, which is a 9% rise compared to Q2 2025. The EBITDA margin also saw an improvement, expanding by 70 basis points to 19.1%.

The adjusted earnings per share (EPS) for the quarter was reported at $1.41, a 19% increase from the previous year, underscoring the company's successful management of costs and pricing amidst inflationary pressures on raw materials. The cash flow from operations improved significantly, reaching a record $121 million, reflecting higher income and efficient operational execution.

Strategic Initiatives

A pivotal highlight of the earnings call was the announcement of H.B. Fuller’s intention to acquire Advanced Medical Solutions (AMS), a strategic move aimed at enhancing its footprint in the medical adhesive market. AMS is recognized for its strong innovation capabilities and a comprehensive product suite in the medical sector, which aligns with H.B. Fuller’s long-term growth strategy. The acquisition is anticipated to generate significant revenue and cost synergies, further solidifying the company's position in a fragmented market characterized by high entry barriers and durable demand trends.

Management emphasized that the deal is part of a larger strategy to transition towards higher-margin and faster-growing markets. The integration of AMS is expected to accelerate the transformation of H.B. Fuller into a business with greater than 20% EBITDA margins by 2030, bolstered by anticipated synergies of approximately $55 million from both commercial and cost rationalization.

Future Outlook

Looking ahead, H.B. Fuller provided guidance for the remainder of fiscal 2026. The company expects net revenue growth to remain in the mid-single digits, with organic revenue projected to increase in the low single digits range. Adjusted EBITDA is anticipated to fall between $650 million and $675 million for the fiscal year, alongside an adjusted EPS forecast ranging from $4.60 to $4.90. The outlook reflects management's confidence in maintaining pricing power despite raw material cost pressures and the anticipated impacts of macroeconomic factors on demand.

For the third quarter, the company expects net revenue growth to be in the mid-single digits, with adjusted EBITDA projected between $180 million and $190 million. Management has indicated that pricing actions taken in April are gaining traction, with expectations of high single-digit pricing performance in the second half of the year.

Closing Assessment

Overall, H.B. Fuller Company reported solid financial results for the second quarter of 2026, driven by effective pricing strategies and operational efficiency. The planned acquisition of Advanced Medical Solutions represents a strategic pivot towards the medical adhesives sector, expected to enhance growth and profitability. Management's outlook remains cautiously optimistic, with a strong commitment to navigating the challenges posed by inflation and supply chain disruptions while capitalizing on growth opportunities. Investors should monitor the integration of AMS closely, as it could significantly impact the company's future performance and market positioning.

This analysis is based on public earnings call materials and is not investment advice.